KR20010051922A - 피리딘 유도체의 제조 방법 - Google Patents
피리딘 유도체의 제조 방법 Download PDFInfo
- Publication number
- KR20010051922A KR20010051922A KR1020000070272A KR20000070272A KR20010051922A KR 20010051922 A KR20010051922 A KR 20010051922A KR 1020000070272 A KR1020000070272 A KR 1020000070272A KR 20000070272 A KR20000070272 A KR 20000070272A KR 20010051922 A KR20010051922 A KR 20010051922A
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- lower alkyl
- mmol
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (14)
- (1a) 하기 화학식 2a의 화합물을 하기 화학식 3의 화합물과 반응시켜 하기 화학식 8a 및 9a의 화합물의 혼합물을 수득하는 단계, 또는(1a') A가 R인 화학식 2a의 화합물을 하나의 반응 단계로 화학식 3의 화합물 및 하기 화학식 5의 화합물과 반응시켜 하기 화학식 4의 화합물을 수득하는 단계;(1b) 상기 (1a) 또는 (1a') 단계에서 수득된 화학식 8a, 9a 또는 4의 화합물을 산화제로 산화시켜 하기 화학식 10 또는 하기 화학식 6의 화합물을 수득하는 단계,(1b') 필요한 경우, 화학식 10의 화합물을 화학식 5의 화합물과 반응시켜 화학식 6의 화합물을 수득하는 단계; 및(1c) 화학식 6의 화합물을 하기 화학식 7의 화합물과 반응시켜 X가 -CON(R5)-인 화학식 1의 화합물을 수득하는 단계; 또는(2d) 화학식 6의 화합물을 하기 화학식 11의 화합물로 변형시키는 단계,(2e) 화학식 11의 화합물을 하기 화학식 12 또는 하기 화학식 13의 화합물과 반응시키는 단계,(2f) 화학식 12 및 화학식 13의 화합물을 R5가 메틸인 하기 화학식 14의 화합물로 변형시키는 단계, 및(2g) 화학식 14의 화합물을 하기 화학식 15의 화합물과 반응시켜 X가 -N(R5)C(O)-인 화학식 1의 화합물을 수득하는 단계를 포함하는, 하기 화학식 1의 화합물 또는 그의 약학적으로 허용가능한 산 부가 염의 제조 방법:화학식 1화학식 2a화학식 3R1Mghal화학식 4화학식 5HR4화학식 6화학식 7화학식 8a화학식 9a화학식 10화학식 11화학식 12화학식 13화학식 14화학식 15상기 식에서,R1은 저급 알킬, 저급 알콕시, 할로겐 또는 트리플루오로메틸로 치환되거나 치환되지 않은 저급 알킬 또는 아릴이고;R2및 R2'는 서로 독립적으로 수소, 할로겐, 트리플루오로메틸, 저급 알콕시 또는 시아노이거나; 또는R2및 R2'는 함께 저급 알킬 또는 저급 알콕시로 치환되거나 치환되지 않은 -CH=CH-CH=CH-일 수 있고;R3및 R3'은 서로 독립적으로 수소 또는 저급 알킬이거나, 또는 이들이 부착된 탄소 원자와 함께 사이클로알킬기를 형성하고;R4는 수소, 저급 알킬, -N(R5)2-, N(R5)(CH2)nOH, -N(R5)S(O)2-페닐, -N(R5)S(O)2-저급 알킬, -N=CH-N(R5)2, -N(R5)C(O)R5, 기또는 기의 사이클릭 3급 아민이고, R5및 R5'는 서로 독립적으로 수소 또는 저급 알킬로 치환되거나 치환되지 않은 저급 알킬 또는 벤질이고;R6는 수소, 하이드록시, 저급 알킬, -(CH2)nCOO-저급 알킬, -N(R5)CO-저급 알킬, 하이드록시-저급 알킬, 시아노, -(CH2)nO(CH2)nOH, -CHO, 또는 알킬렌기를 통해 결합되거나 결합되지 않은 5원 또는 6원 헤테로사이클릭기이고;n은 0 내지 4이고;A는 R 또는 R4이고;R은 할로겐이고;X는 -C(O)N(R5)- 또는 -N(R5)C(O)-이고;hal은 할로겐 원자이다.
- 제 1 항에 있어서,(1a) 하기 화학식 2a의 화합물을 하기 화학식 3의 화합물과 반응시켜 하기 화학식 8a 및 하기 화학식 9a의 화합물의 혼합물을 수득하는 단계, 또는(1a') A가 R인 화학식 2a의 화합물을 화학식 3의 화합물 및 하기 화학식 5의 화합물과 반응시켜 하기 화학식 4의 화합물을 수득하는 단계를 포함하는 방법:화학식 2a화학식 3R1Mghal화학식 4화학식 5HR4화학식 8a화학식 9a상기 식에서,A는 R 또는 R4이고;R은 할로겐이고;hal은 할로겐 원자이고;R1, R4, R5및 R5'는 제 1 항에서 정의된 바와 같다.
- 제 1 항에 있어서,제 2 항에 기재된 단계 (1a)에서 용매가 THF인 방법.
- 제 1 항에 있어서,단계 (1b)에서 산화제가 Mn(OAc)3, Cu(OAc)2, 요오드, 브롬, N-브로모숙신이미드, Pd/C, Pt/C, DDQ(2,3-디클로로-5,6-디시아노-1,4-벤조퀴논), o-클로라닐, H2O2-우레아, Na2CO3-H2O2, MnO2, KMnO4, RuCl2(PPh3)3Cer(IV)암모늄니트레이트, HNO3및 S로 구성된 군에서 선택된 방법.
- 제 1 항에 있어서,단계 (1c)에서 포타슘 비스(트리메틸실릴)아미드의 존재하에서 THF중에서 반응을 수행하는 방법.
- 제 1 항에 있어서,단계 (1c)에서 N-(3,5-비스-트리플루오로메틸-벤질)-N-메틸-6-(4-메틸-피페라진-1-일)-4-o-톨릴-니코틴아미드를 수득하는 방법.
- 제 1 항에 있어서,단계 (2d)에서 황산 및 AcOH 또는 메탄설폰산의 존재하에서 반응을 수행하는 방법.
- 제 1 항에 있어서,단계 (2e)에서 아미노 치환기를 호프만(Hofmann) 재배열을 통해 도입하는 방법.
- 제 1 항에 있어서,단계 (2f)에서 화학식 12의 화합물을 출발 물질로 사용하여 화학식 14의 화합물을 제조하기 위한 반응을 알킬 오르토포르메이트, 촉매량의 산 및 환원제에 의해 수행하는 방법.
- 제 9 항에 있어서,알킬 오르토포르메이트가 HC(OCH3)3이고 산이 트리플루오로 아세트산인 방법.
- 제 9 항에 있어서,환원제가 LiAlH4, NaBH4, BH3-THF 또는 레드-알(Red-Al: 등록상표)인 방법.
- 제 1 항에 있어서,단계 (2f)에서 화학식 13의 화합물을 출발 물질로 사용하여 화학식 14의 화합물을 제조하기 위한 반응을 LiAlH4또는 레드-알(등록상표)에 의해 수행하는 방법.
- 제 1 항에 있어서,단계 (2g)에서 반응을 3급 아민의 존재하에 수행하는 방법.
- 제 1 항에 있어서,단계 (2g)에서 수득된 화합물이 2-(3,5-비스-트리플루오로메틸-페닐)-N-메틸-N-(6-모르폴린-4-일-4-o-톨릴-피리딘-3-일)-이소부티르아미드인 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99123686.0 | 1999-11-29 | ||
EP99123686 | 1999-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010051922A true KR20010051922A (ko) | 2001-06-25 |
KR100371121B1 KR100371121B1 (ko) | 2003-02-06 |
Family
ID=8239482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-0070272A KR100371121B1 (ko) | 1999-11-29 | 2000-11-24 | 피리딘 유도체의 제조 방법 |
Country Status (12)
Country | Link |
---|---|
US (1) | US6303790B1 (ko) |
EP (1) | EP1103546B1 (ko) |
JP (1) | JP3403164B2 (ko) |
KR (1) | KR100371121B1 (ko) |
CN (1) | CN1176908C (ko) |
AT (1) | ATE252559T1 (ko) |
CA (1) | CA2326815C (ko) |
DE (1) | DE60006054T2 (ko) |
DK (1) | DK1103546T3 (ko) |
ES (1) | ES2208206T3 (ko) |
JO (1) | JO2252B1 (ko) |
MX (1) | MXPA00011670A (ko) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE1035115T5 (sv) * | 1999-02-24 | 2015-08-04 | Hoffmann La Roche | 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister |
ATE253561T1 (de) * | 1999-11-29 | 2003-11-15 | Hoffmann La Roche | 2-(3,5-bis-trifluoromethyl-phenyl)-n-methyl-n-( - morpholin-4-yl-4-o-tolyl-pyridin-3-yl)- isobutyramid |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
PT1474395E (pt) * | 2002-02-12 | 2008-01-02 | Smithkline Beecham Corp | Derivados de nicotinamida úteis como inibidores de p38 |
TWI280239B (en) | 2003-07-15 | 2007-05-01 | Hoffmann La Roche | Process for preparation of pyridine derivatives |
JP4580426B2 (ja) | 2004-07-06 | 2010-11-10 | エフ.ホフマン−ラ ロシュ アーゲー | Nk−1受容体拮抗薬の合成において中間体として使用されるカルボキサミド誘導体の製造方法 |
KR20070094666A (ko) | 2005-02-25 | 2007-09-20 | 에프. 호프만-라 로슈 아게 | 약제 물질 분산성이 향상된 정제 |
CN103893145A (zh) * | 2005-09-23 | 2014-07-02 | 弗·哈夫曼-拉罗切有限公司 | 新型制剂 |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
CN105358153A (zh) | 2013-07-02 | 2016-02-24 | 尤斯特拉里斯制药有限公司(以普雷舒拉纽罗作为商号) | 用于预防和/或治疗ii型慢性创伤性脑病的方法 |
CN104003933A (zh) * | 2014-05-14 | 2014-08-27 | 上海应用技术学院 | 一种含氟基团的3-(吡啶基-2-亚胺)丙酸乙酯类似物的制备方法 |
CN105061303A (zh) * | 2015-08-03 | 2015-11-18 | 成都欣捷高新技术开发有限公司 | 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法 |
CN105732488B (zh) * | 2016-03-28 | 2018-02-16 | 大连理工大学 | 一种吡啶‑2‑甲酸脱羧合成2‑(2‑氯乙氧基)乙氧基吡啶醚化合物的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4745123A (en) | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
SE1035115T5 (sv) | 1999-02-24 | 2015-08-04 | Hoffmann La Roche | 4-fenylpyridin-derivat och deras anvaendning som NK-1 receptor-antagonister |
-
2000
- 2000-11-20 US US09/716,538 patent/US6303790B1/en not_active Expired - Lifetime
- 2000-11-23 JO JO2000186A patent/JO2252B1/en active
- 2000-11-23 DE DE60006054T patent/DE60006054T2/de not_active Expired - Lifetime
- 2000-11-23 AT AT00125665T patent/ATE252559T1/de active
- 2000-11-23 ES ES00125665T patent/ES2208206T3/es not_active Expired - Lifetime
- 2000-11-23 EP EP00125665A patent/EP1103546B1/en not_active Expired - Lifetime
- 2000-11-23 CA CA002326815A patent/CA2326815C/en not_active Expired - Lifetime
- 2000-11-23 DK DK00125665T patent/DK1103546T3/da active
- 2000-11-24 KR KR10-2000-0070272A patent/KR100371121B1/ko active IP Right Grant
- 2000-11-27 MX MXPA00011670A patent/MXPA00011670A/es active IP Right Grant
- 2000-11-28 CN CNB001283839A patent/CN1176908C/zh not_active Expired - Lifetime
- 2000-11-28 JP JP2000360682A patent/JP3403164B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2001151755A (ja) | 2001-06-05 |
DE60006054T2 (de) | 2004-07-22 |
EP1103546B1 (en) | 2003-10-22 |
CN1176908C (zh) | 2004-11-24 |
CA2326815C (en) | 2009-08-25 |
MXPA00011670A (es) | 2002-08-20 |
CN1297887A (zh) | 2001-06-06 |
CA2326815A1 (en) | 2001-05-29 |
JO2252B1 (en) | 2004-10-07 |
DE60006054D1 (de) | 2003-11-27 |
JP3403164B2 (ja) | 2003-05-06 |
DK1103546T3 (da) | 2004-02-23 |
ES2208206T3 (es) | 2004-06-16 |
KR100371121B1 (ko) | 2003-02-06 |
EP1103546A1 (en) | 2001-05-30 |
ATE252559T1 (de) | 2003-11-15 |
US6303790B1 (en) | 2001-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100371121B1 (ko) | 피리딘 유도체의 제조 방법 | |
AU2002212118B2 (en) | 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists | |
US6297375B1 (en) | 4-phenyl-pyridine derivatives | |
CA2415890C (en) | N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives | |
JP5539235B2 (ja) | アミド化合物、組成物およびそれらの使用 | |
US5250548A (en) | Angiotensin II receptor antagonists | |
CA1334972C (en) | Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds | |
AU2002212118A1 (en) | 4-phenyl-pyridine derivatives as Neurokinin-1 receptor antagonists | |
TWI280239B (en) | Process for preparation of pyridine derivatives | |
EP0228845B1 (en) | N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same | |
KR20000053314A (ko) | 치환된 피리딘의 제조 방법 | |
JP3135170B2 (ja) | アミノメチル置換2,3−ジヒドロピラノ〔2,3−b〕ピリジン類 | |
KR20000022045A (ko) | 5-ht-2c 수용체 길항제로 유용한 인돌린 유도체 | |
WO1997022588A1 (en) | Use of hetarylacetic acid derivatives as leukotriene inhibitors | |
KR100546992B1 (ko) | 4,5-다이아미노 피리미딘 유도체 및 이의 제조방법 | |
JPWO2010001990A1 (ja) | 四環系化合物 | |
JPH01193249A (ja) | アザタジン用中間体 | |
MXPA99004459A (en) | Process for substituted pyridines | |
JP2003055345A (ja) | ビフェニルカルボキサミドイソインドリン誘導体、その製法およびその合成中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121227 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20131227 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20141230 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20151230 Year of fee payment: 14 |
|
FPAY | Annual fee payment |
Payment date: 20161229 Year of fee payment: 15 |
|
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 16 |
|
FPAY | Annual fee payment |
Payment date: 20181227 Year of fee payment: 17 |